Myriad Genetics, Inc.
Myriad Genetics develops genetic tests for oncology, womens health, and pharmacogenomics. They offer several DNA sequencing tests, including MyRisk and BRACAnalysis CDx. Other products include Prolaris (prostate cancer), EndoPredict (breast cancer), and Precise Tumor (precision oncology). The company also offers non-invasive prenatal screening tests, including Prequel and Foresight Carrier Screen. Additionally, they offer GeneSight for psychotropic medication selection. Myriad Genetics has strategic collaborations with several organizations. The company was incorporated in 1992 and is headquartered in Utah.
Overview
Strengths
- Price to book ratio (0.66) is lower than the sector mean (9.96).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (7.40%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (36.02).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |